Brief: Abionyx Pharma Acknowledges Phase 3 Aegis-II Study Did Not Meet Primary Efficacy Endpoint Of Mace Reduction At 90 Days

Abionyx Pharma SA

15/02/2024 17:05

Feb 15 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX PHARMA ACKNOWLEDGES THE CLINICAL RESULTS OF THE
PHASE 3
AEGIS-II STUDY EVALUATING THE EFFICACY AND SAFETY OF CSL
BEHRING’S HUMAN-PLASMA-DERIVED APOA-I, CSL112
    * TODAY ACKNOWLEDGES THAT PHASE 3 AEGIS-II STUDY DID NOT
MEET ITS
PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS

Source text for Eikon:  ID:nBw99Jsa 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))